What you should know:
1. WuXi developed the biologics conjugation center in June 2018.
2. The expanded center will span 5.5 acres and will allow the company to commercially manufacture antibody-drug conjugate products.
4. WuXi is currently developing more than 20 antibody-drug conjugates.
More articles on biologics:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
